Navigation Links
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Date:7/22/2009

ven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

About Asthma

Asthma is a chronic lung disease characterized by inflammation of the air passages, resulting in the temporary narrowing of the airways that transport air from the nose and mouth to the lungs.(2) Asthma symptoms can be triggered by allergens or irritants and can include difficulty breathing, wheezing, coughing, shortness of breath and tightness in the chest.(2) With more than 22 million people living with asthma in the United States(3), it is one of the most common and costly chronic diseases.(2) Annually, this disease leads to almost two million asthma-related emergency room visits and more than 4,000 asthma-related deaths in the United States.(2) There is no cure for asthma, but asthma can be managed with proper treatment.(2)( )( )

About ASMANEX((R))

ASMANEX((R)) TWISTHALER((R)) (mometasone furoate inhalation powder) is for the maintenance treatment of asthma in patients 4 years of age and older. ASMANEX TWISTHALER will not relieve sudden asthma symptoms and is not for children under the age of 4.

ASMANEX TWISTHALER is available in two dose strengths, 110 mcg for children between 4 and 11 years old, and 220 mcg for patients 12 and older.

Important Safety I
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... Medicity Institute (Medicity) has approved a treatment program entitled: ... Infection in Combination with Standard of Care (SOC) Drug ...
... will help its guests reach their well-being goals by ... cold and flu season. Beginning Sept. 1, 2010, the ... Target Pharmacy and Target Clinic locations nationwide. Continuing its ... again offering the seasonal flu vaccine at the low ...
Cached Medicine Technology:Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 3Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 4Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 5Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 6Target to Serve as Prevention HQ this Flu Season 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow from ... at an expected CAGR of 9.7% for the period ... increasing number of security breaches, continued line of sophisticated ... organizations are enormous. Vendors in the security analytics market ... develop better and more secure systems. , There has ...
(Date:7/12/2014)... 2014 (HealthDay News) -- Burn injuries increase in the summer ... say burn experts. Among those most vulnerable to these seasonal ... vulnerable and often get burned by putting their hands on ... of the burn unit at Loyola University Medical Center in ... old adage of ,When you play with fire, you get ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... 12, 2014 Doylestown Hospital recently conducted ... of men’s health questions. Paddock tackles topics including ... why women live longer than men, and testosterone replacement ... Made Simple featured on Doylestown Hospital’s website, Dr. ... at any age. If you notice pain, bulging, or ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... French . , Recent animal studies have ... used to treat diarrhea and other gastrointestinal disorders ... diseases. Scientists, however, had a variety of theories to ... such similar effects on three unrelated neurodegenerative disorders. , ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that ... Conference on January 14 in San Francisco.A live broadcast of ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... be available for 30 days, and can be accessed at ...
... Jan. 6, Halo Pharmaceutical, Inc., a privately ... completion of its acquisition of the Whippany-NJ Manufacturing ... ABT ). At over 200,000 square feet, ... including an impressive array of formulation services, operations ...
... remain stableWASHINGTON, Jan. 6 Karen Ignagni, President and CEO ... data released by CMS today showing that health spending in ... decade at 6.1 percent in 2007. According to the ... 2007, the same rate as in 2006, but much lower ...
... UCSF has received a $7.5 million grant from the Bill & ... to help address Africa,s urgent need for healthcare workers. , ... ... San Francisco has received a $7.5 million grant from the Bill ...
... With 30 million drivers in the US aged 65 ... they can no longer drive safely and decide that it,s ... that a decrease in vision function is a key factor ... and Driving Study (SEEDS) ( http://www.iovs.org/cgi/content/full/50/1/107 ), conducted by researchers ...
Cached Medicine News:Health News:Old gastrointestinal drug slows aging, McGill researchers say 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 3Health News:Vision problems prompt older drivers to put down the keys 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: